<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">27085492</PMID>
        <DateCompleted>
            <Year>2016</Year>
            <Month>12</Month>
            <Day>13</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>02</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1471-2407</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>16</Volume>
                    <PubDate>
                        <Year>2016</Year>
                        <Month>Apr</Month>
                        <Day>16</Day>
                    </PubDate>
                </JournalIssue>
                <Title>BMC cancer</Title>
                <ISOAbbreviation>BMC Cancer</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Short-term culture of tumour slices reveals the heterogeneous sensitivity of human head and neck squamous cell carcinoma to targeted therapies.</ArticleTitle>
            <Pagination>
                <MedlinePgn>273</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12885-016-2318-x</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Despite recent progress, investigating the impact of targeted therapies on Head and Neck Squamous Cell Carcinoma (HNSCC) remains a challenge. We investigated whether short-term culture of tumour fragments would permit the evaluation of tumour sensitivity to targeted therapies at the individual level.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">We cultivated tumour slices prepared from 18 HNSCC tumour samples obtained during surgical resection. The samples were treated for 48 h with a panel of 8 targeted therapies directed against selected oncogenic transduction pathways. We analysed the cell proliferation index (CPI) of tumour cells using Ki67 labelling and the activation status of the RAF-MEK-ERK cascade through ERK phosphorylation analysis.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Fourteen tumours were successfully analysed after short-term culture of tumour samples, revealing a striking individual heterogeneity of HNSCC in terms of tumour cell sensitivity to targeted therapies. Using 50% inhibition of CPI as threshold, sorafenib was shown to be active in 5/14 tumours. Cetuximab, the only approved targeted drug against HNSCC, was active in only 2/14 tumours. A more than 50% inhibition was observed with at least one drug out of the eight tested in 10/14 tumours. Cluster analysis was carried out in order to examine the effect of the drugs on cell proliferation and the RAF-MEK-ERK cascade.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In vitro culture of tumour fragments allows for the evaluation of the effects of targeted therapies on freshly resected human tumours, and might be of value as a possible guide for the design of clinical trials and for the personalization of the medical treatment of HNSCC.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Donnadieu</LastName>
                    <ForeName>Jérôme</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Head and Neck Surgery, University Hospital, Amiens, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lachaier</LastName>
                    <ForeName>Emma</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, University Hospital, Amiens, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Peria</LastName>
                    <ForeName>Marine</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Head and Neck Surgery, University Hospital, Amiens, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Saidak</LastName>
                    <ForeName>Zuzana</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biochemistry, University Hospital, Amiens, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dakpe</LastName>
                    <ForeName>Stéphanie</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Maxillofacial Surgery, University Hospital, Amiens, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ikoli</LastName>
                    <ForeName>Jean-Fortune</ForeName>
                    <Initials>JF</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, University Hospital, Amiens, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chauffert</LastName>
                    <ForeName>Bruno</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, University Hospital, Amiens, France.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>EA4666, Université de Picardie-Jules Verne (UPJV), Amiens, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Page</LastName>
                    <ForeName>Cyril</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Head and Neck Surgery, University Hospital, Amiens, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Galmiche</LastName>
                    <ForeName>Antoine</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biochemistry, University Hospital, Amiens, France. galmiche.antoine@chu-amiens.fr.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>EA4666, Université de Picardie-Jules Verne (UPJV), Amiens, France. galmiche.antoine@chu-amiens.fr.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2016</Year>
                <Month>04</Month>
                <Day>16</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>BMC Cancer</MedlineTA>
            <NlmUniqueID>100967800</NlmUniqueID>
            <ISSNLinking>1471-2407</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D019394">Ki-67 Antigen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.11.1</RegistryNumber>
                <NameOfSubstance UI="D019908">Proto-Oncogene Proteins c-raf</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.11.25</RegistryNumber>
                <NameOfSubstance UI="D048748">MAP Kinase Kinase Kinase 3</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.12.2</RegistryNumber>
                <NameOfSubstance UI="D048369">MAP Kinase Kinase 1</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>PQX0D8J21J</RegistryNumber>
                <NameOfSubstance UI="D000068818">Cetuximab</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002294" MajorTopicYN="N">Carcinoma, Squamous Cell</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018929" MajorTopicYN="Y">Cell Culture Techniques</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000068818" MajorTopicYN="N">Cetuximab</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006258" MajorTopicYN="N">Head and Neck Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019394" MajorTopicYN="N">Ki-67 Antigen</DescriptorName>
                <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D048369" MajorTopicYN="N">MAP Kinase Kinase 1</DescriptorName>
                <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D048748" MajorTopicYN="N">MAP Kinase Kinase Kinase 3</DescriptorName>
                <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D058990" MajorTopicYN="Y">Molecular Targeted Therapy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D057285" MajorTopicYN="N">Precision Medicine</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019908" MajorTopicYN="N">Proto-Oncogene Proteins c-raf</DescriptorName>
                <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000077195" MajorTopicYN="N">Squamous Cell Carcinoma of Head and Neck</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Head and neck squamous cell carcinoma</Keyword>
            <Keyword MajorTopicYN="N">Short-term culture of tumour fragments</Keyword>
            <Keyword MajorTopicYN="N">Targeted therapies</Keyword>
            <Keyword MajorTopicYN="N">Treatment personalization</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2015</Year>
                <Month>06</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2016</Year>
                <Month>04</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2016</Year>
                <Month>4</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2016</Year>
                <Month>4</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2016</Year>
                <Month>12</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">27085492</ArticleId>
            <ArticleId IdType="doi">10.1186/s12885-016-2318-x</ArticleId>
            <ArticleId IdType="pii">10.1186/s12885-016-2318-x</ArticleId>
            <ArticleId IdType="pmc">PMC4834185</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Br J Cancer. 2014 Jan 21;110(2):479-88</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24263061</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Anticancer Res. 2013 Apr;33(4):1415-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23564781</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2008 Sep 11;359(11):1116-27</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18784101</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Eur J Cancer. 2009 May;45(7):1117-28</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19124237</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2010 May;21 Suppl 5:v184-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20555077</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer Ther. 2010 Jun;9(6):1544-53</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20484018</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2010 May 4;107(18):8352-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20404174</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2015 Jan 29;517(7536):576-82</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25631445</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell. 2015 Feb 26;160(5):977-89</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25723171</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Cancer. 2015 Jun 15;136(12):2940-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25404014</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Head Neck. 2016 Apr;38 Suppl 1:E911-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25994489</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Head Neck. 1998 Jul;20(4):320-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9588705</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2006 Feb 9;354(6):567-78</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16467544</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMC Cancer. 2006;6:86</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16603054</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Expert Rev Mol Diagn. 2011 Mar;11(2):171-82</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21405968</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Biotechnol. 2011 Nov;29(11):1046-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22037378</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer Ther. 2012 Mar;11(3):690-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22238366</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell. 2012 Oct 26;151(3):465-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23101617</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2007 Jun 1;25(16):2171-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17538161</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>